GLOBAL FORECAST OF THE FACTORS VIII AND IX MARKETS BY REGION, PRODUCT AND COMPANY FROM 2015 TO 2020
PROPOSAL FOR A SYNDICATED STUDY
After nearly two decades without much novelties in the area of coagulation factors, the recent introduction of new recombinant products and more to come in the near future will undoubtedly bring a sea change in hemophilia care. Hemophilia patients in the industrialized world will have access to a wider choice of new factor products, both standard and Extended Half-Life (long-acting), while those living in third-world countries will benefit from a higher availability of plasma-derived products as well as of low-cost recombinants. As in the 1990s, when recombinant factors VIII and IX first came out, the worldwide supply of factor products will increase, offering better care to many patients through greater access to factors VIII and IX concentrates.
In 2014, Biogen IDEC introduced Eloctate and Alprolix, the first long-acting recombinant factors, allowing hemophilia patients to enjoy an improved lifestyle, as these new types of clotting factors require less frequent infusions without compromising safety and efficacy. The larger selection of factor products is expected to increase competition, possibly resulting in some price erosion, easing up the patients’ financial burden. Furthermore, they will allow some patients to adopt lifelong prophylaxis or maintain higher through levels.
In view of the importance of these forthcoming market changes, the Marketing Research Bureau has undertaken to forecast factors VIII and IX sales by company and by product category in all major regions from 2013 to 2020.